The Slovak Ministry of Health faced a significant setback as it lost a legal dispute in administrative court against private health insurers Dôvera and Union concerning the obligation to cover the high-cost drug Zolgensma. This ruling, announced last Thursday, brings into question the financial responsibilities of health insurers in Slovakia towards patients in need of this life-saving treatment. The ministry has yet to comment on the court's decision or indicate whether an appeal will be pursued, leaving uncertainty for stakeholders in the healthcare system.

Zolgensma is recognized for its potential to treat spinal muscular atrophy (SMA), a debilitating condition that has no current cure. The drug's exorbitant price, reportedly in the millions of euros, poses a substantial challenge for health insurers and the government, particularly in light of recent decisions by the Ministry of Health to mandate that health insurers cover such high-cost medications under the public health system. The case has drawn national attention, particularly with the widely publicized story of a young patient, Editka, whose family pursued legal avenues due to the denial of coverage for her necessary treatment.

This legal ruling not only signifies a defeat for the Ministry of Health but also highlights broader implications for the healthcare system in Slovakia. It raises questions about the sustainability of funding for advanced medical treatments and the roles of private insurers versus public funding in ensuring that patients receive crucial therapies. As the ministry grapples with this legal blow, the future accessibility of potentially life-saving medications like Zolgensma remains uncertain for patients in need.